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Edited by Y. Shi: A catalytic triad in OspI selectively deamidates
f Ubc13 to Glu, and this modification suppresses
am inflammatory signaling during bacterial infec-
structure of the OspI–Ubc13 complex provides
hanism of substrate recognition.Abstract
Ubc13 is a ubiquitin-conjugating enzyme that plays a
key role in the nuclear factor-κB signal transduction
pathway in human diseases. The Shigella flexneri
effector OspI affects inflammatory responses by
catalyzing the deamidation of a specific glutamine
residue at position 100 in Ubc13 during infection. This
modification prevents the activation of the TNF (tumor
necrosis factor) receptor-associated factor 6, leading
to modulation of the diacylglycerol–CBM (CARD–
Bcl10–Malt1) complex–TNF receptor-associated fac-
tor 6–nuclear factor-κB signaling pathway. To eluci-
date the structural basis of OspI function, we
determined the crystal structures of the catalytically
inert OspI C62Amutant and its complex with Ubc13 at
resolutions of 3.0 and 2.96 Å, respectively. The
structure of the OspI–Ubc13 complex revealed that
the interacting surfaces between OspI and Ubc13 are
a hydrophobic surface and a complementary charged
surface. Furthermore, we predict that the complemen-
tary charged surface of OspI plays a key role in
substrate specificity determination.
© 2013 Elsevier Ltd.Open access under CC BY-NC-ND license.J. Mol. Biol. (2013) 425, 2623–2631
2624 Recognition of Ubc13 by OspIIntroductiondeliver virulence factors, called effectors, into host
cells through the type III secretion system. To
(C62A, C62S and C65S) and performed in vitro
pull-down analysis. As shown in Fig. 1a, the OspINumerous Gram-negative pathogenic bacteria
establish infection, some effectors mimic or hijack
the host signaling pathway, whereas others interfere
with the host's innate immune system.1
Ubiquitination is one of the most prevalent post-
translational modifications. Protein ubiquitination is
catalyzed by a sophisticated cascade system consist-
ing of ubiquitin-activating (E1), ubiquitin-conjugating
(E2), and ubiquitin-ligating (E3) enzymes. Among
these enzymes, E3 enzymes are responsible for the
selection of target proteins. E3 enzymes are a diverse
family of proteins [RING (really interesting new gene)
or HECT (homologous to E6-associated protein
C terminus type)] and multiple protein complexes.2
TNF (tumor necrosis factor) receptor-associated
factor 6 (TRAF6) is a RING-type E3 ligase. TRAF6
regulates the nuclear factor-κB activation signaling
pathway to induce immune and inflammatory re-
sponses and confer protection against apoptosis.
TRAF6 functions with a heterodimer E2 that consists
of Ubc13 and a ubiquitin E2 variant (Uev1A) to
synthesize K63-linked polyubiquitin chains on target
proteins and TRAF6 itself.3 This K63-linked poly-
ubiquitination leads to the activation of the down-
stream signaling pathway. Unlike K48-linked
polyubiquitin chains that are hallmarks of proteaso-
mal degradation, K63-linked polyubiquitin is nonde-
gradative and has been shown to function as a
signaling moiety in DNA damage repair processes
and innate immunity pathways.4,5
OspI, a Shigella flexneri effector, is a glutamine
deamidase that selectively deamidates the glutamine
residue at position 100 in Ubc13 to a glutamic acid
residue. This modification inhibits the E2 ubiquitin-
conjugating activity, which is required for TRAF6
activation, and leads to the suppression of TRAF6-
dependent inflammatory signaling during bacterial
infection. We recently determined the OspI crystal
structure, which has a cysteine protease-like fold and
a conserved active-site catalytic triad (Cys62, His145,
and Asp160).6 Mutation of the catalytic triad caused
OspI to lose its Ubc13 deamidation activity. To better
understand the mechanistic details underlying OspI-
mediated TRAF6 inhibition, we determined the crystal
structures of the OspI C62A–Ubc13 complex and the
OspI C62A mutant.Results and DiscussionOverall structure of the OspI–Ubc13 complex
To define how OspI engages its substrate and
catalyzes the deamidation of Ubc13, we attemptedto crystallize OspI–Ubc13 complexes. To compar-
atively assess the binding of OspI to Ubc13, we
generated catalytic cysteine-inactive mutants
C62A mutant showed increased binding to Ubc13
compared with wild-type OspI. Therefore, we used
an OspI C62A mutant for crystallization with Ubc13.
We obtained crystals of OspI C62A in complex with
Ubc13 and determined the structure by themolecular
replacement method (Fig. 1b and Table 1). The
refined structure model contains residues 21–212 of
OspI C62A, residues 1–152 of Ubc13, and four iodine
atoms. The structure of OspI has an α/β fold, with four
β-strands (β1–β4), seven α-helices (α1–α7), and a
310 helix (310-1). The electron densities of the N-
terminal domain (residues 1–21) of OspI are not
visible, suggesting that this region is flexible. Ubc13
adopts a canonical E2 fold, consisting of a four-
stranded antiparallel β-sheet (S1–S4), four α-helices
(H1–H4), and a 310 helix (310-1). The folds of theOspI
C62A and Ubc13 in the complex were almost
identical with those of each free form (Fig. 1c). The
root-mean-square deviation (r.m.s.d.) of the Cα
atoms between free and Ubc13-bound OspI was
1.2 Å for 191 residues, whereas that of the Cα atoms
between free and OspI-bound Ubc13 was 1.7 Å for
148 residues. However, the H1 helix of Ubc13 had a
different conformation when Ubc13 was bound to
OspI. The N-terminal end of the H1 helix had shifted
about 1.8 Å closer to OspI (Fig. S1).Interaction between OspI and Ubc13
The structure of the OspI–Ubc13 complex
revealed that OspI and Ubc13 are bound by
interactions of 310-1 and loops α2–α3, 310-1–α4,
β1–β2, and β3–β4 of OspI with H1, H2, and loops
S3–S4 and 310-1–H2 of Ubc13 (Fig. 2a and Fig.
S2). A total of 970 Å2 of the accessible surface area
is buried at the interface between OspI and Ubc13.
Ubc13 is bound to OspI by its S3–S4 and 310-1–H2
loops against the concave surface of OspI, and
Ubc13 extends its Gln100 to the active site of OspI.
The residues involved in intermolecular formation
are Asp59, Gly60, Ser63, Ile87, Thr92, Phe95,
Asp103, Glu141, Gln142, Ala143, Thr144, Tyr170,
and Asn184 of OspI and Gly3, Leu4, Arg6, Arg7,
Arg14, Met64, Ser96, Pro97, Ala98, Leu99, Gln100,
Thr103, and Leu106 of Ubc13. Gly60, Glu141,
Gln142, Thr144, and Asn184 of OspI form a
potential salt bridge and hydrogen bond with
Ala98 and Arg6 of Ubc13, respectively (Fig. S2).
The interacting surfaces of these two proteins are a
hydrophobic surface and a complementary charged
surface (Fig. 2b). To investigate the roles of
residues involved in complex formation, we intro-
duced point mutations into OspI and Ubc13. We
Fig. 1. Crystal structure of the OspI C62A–Ubc13 complex. (a) Ubc13 binding activity of OspI mutants. Pull-down
analysis using GST–OspI mutants with Ubc13. GST–OspI wild type and its mutants were expressed in BL21. The cell
extracts were incubated with glutathione–Sepharose 4B, and the immobilized proteins were washed extensively with a
pull-down buffer [25 mM Tris–HCl (pH 7.5), 20 mM 2-mercaptoethanol, and 150 mM NaCl]. His–Ubc13 and its mutants
were expressed in BL21, purified by Ni-NTA affinity chromatography and anion-exchange chromatography, and dialyzed
in the pull-down buffer. The resulting immobilized glutathione–Sepharose 4B containing GST–OspI wild type or its mutants
were incubated with 40 μM Ubc13 and its mutants in 200 μl of the pull-down buffer on ice for 1 h and then washed two
times. GST-bound proteins were suspended in SDS-PAGE sample buffer and subjected to SDS-PAGE, followed by
Coomassie Brilliant Blue staining. (b) A ribbon diagram of the OspI C62A–Ubc13 complex. OspI C62A and Ubc13 are
colored blue and orange, respectively. Secondary structural elements are labeled. The side chains of the active-site
residues (A62–H145–D160) of OspI and Q100 of Ubc13 are shown in stick models. (c) Structural comparison of OspI
(PDB code 3B21; magenta) and Ubc13 (PDB code 1JBB; green) in their free forms and in the OspI C62A–Ubc13 complex.
The molecular orientation is the same as that in (b).
2625Recognition of Ubc13 by OspImutated selected residues of the OspI C62A–Ubc13
interface to Ala (R6A, R14A, M64A, and L99A) in
Ubc13 and conducted a glutathione S-transferase
(GST) pull-down experiment to monitor complex
formation (Fig. 2c, left). The R6A and L99A mutants
showed very weak binding to OspI. Mutation M64A
also reduced binding. However, the R14A mutant
had no effect. This result suggested that R6, M64,
and L99 of Ubc13 participate in OspI binding. We
investigated substrate deamidation with a series of
Ubc13 mutants using native PAGE (Fig. S3).
Consistent with their very weak binding, the R6A
and L99A mutants were not deamidated by OspI.
Although the M64A mutant showed reduced binding
to OspI, the reduced binding was sufficient fordeamidation. The R14A mutation did not affect
binding to OspI and was deamidated by OspI. Next,
we created a series of OspI mutants to determine
the residues important for OspI–Ubc13 complex
formation. We performed an in vitro pull-down assay
with OspI mutants and Ubc13 (Fig. 2c, right). We
found that OspI I87A, F95A, and Q142A mutants
showed a decreased ability to bind to Ubc13
compared with the C62A mutant. In addition, we
investigated the substrate deamidation activity with
a series of OspI mutants using native PAGE. As
shown in Fig. 2d, OspI mutants I87A, F95A, and
Y170A have relatively low deamidation activity.
These results suggest that the hydrophobic in-
teractions are crucial for OspI–Ubc13 binding.
Table 1. Crystallographic data collection and refinement statistics
OspI C62A–Ubc13 complex OspI C62A mutant
Data collection
Wavelength (Å) 0.9 0.9
Space group P321 P212121




Resolution (Å) 50.0–2.96 (3.00–2.96) 50.0–3.00 (3.05–3.00)
No. of measured reflections 56,970 49,134
No. of unique reflections 12,193 8194
Completeness (%) 99.8 (100.0) 99.9 (100.0)
Redundancy 3.4 (3.5) 6.0 (5.7)
Mean I/σ(I) 13.3 (4.2) 12.5 (5.3)
Rmerge (%) 9.4 (30.0) 16.0 (29.4)
Structure refinement
Resolution range (Å) 33.14–2.96 41.63–3.00
No. of reflections 12,150 7750
Rcryst (%) 24.5 24.8
Rfree (%) 28.6 26.9
r.m.s.d. bond lengths (Å) 0.009 0.003
r.m.s.d. bond angles (°) 1.381 0.404
No. of protein atoms 2699 2980





Most favored region 77.0 84.1
Additional allowed 21.0 15.9
Generously allowed 2.0 0
Values in parentheses are for the highest-resolution shell.
OspI and its mutants were cloned into the pGEX6P-1 vector and expressed in Escherichia coli BL21. OspI was purified in a stepwise
process using glutathione–Sepharose 4B, anion-exchange chromatography, and gel-filtration chromatography. The GST moiety was
proteolytically removed by PreScission protease. For the OspI–Ubc13 complex, we used the OspI C62A mutant and His–Ubc13. Ubc13
was cloned into the pET28 vector and expressed in E. coli BL21. Ubc13 was purified by Ni-affinity chromatography, and the His tag was
cleaved from Ubc13 using thrombin. The OspI C62A mutant and Ubc13 were combined and purified by gel-filtration chromatography.
Fractions containing the OspI C62A–Ubc13 complex were then concentrated to 51 mg/ml and used for crystallization. OspI C62A was
concentrated to 40 mg/ml by ultrafiltration in 25 mM Tris–HCl (pH 7.5) and 1 mM DTT. Crystallization of the OspI C62A mutant was
performed using the sitting-drop vapor-diffusion method at 293 K in drops containing a mixture of 1 μl of protein solution and 1 μl of
reservoir solution, which consisted of 0.2 M magnesium acetate, 0.1 M Tris–HCl (pH 6.5), and 25% (w/v) polyethylene glycol 8000. The
OspI C62A–Ubc13 crystals were prepared using the hanging-drop vapor-diffusion method at 293 K in drops containing a mixture of 1 μl of
protein solution and 1 μl of reservoir solution, which consisted of 0.4 M potassium iodide, 0.1 M 4-morpholineethanesulfonic acid (pH 6.5),
4 mM DTT, and 15% polyethylene glycol 8000. X-ray diffraction data sets for OspI C62A and the OspI C62A–Ubc13 complex were
collected at 100 K on BL44XU (SPring-8). Data processing and reduction were conducted with HKL2000.7 The structure of the OspI C62A
mutant was determined by molecular replacement in MOLREP8,9 using as a search model the wild-type OspI (PDB ID 3B21) structure6
lacking residues 59–77. The structure of the OspI C62A–Ubc13 complex was determined using the molecular replacement technique
PHENIX10 and the wild-type OspI and Ubc1311 (PDB ID 1JBB). The models were subsequently improved through alternate cycles of
manual rebuilding using Coot12 and refinement with the program REFMAC513 and CNS.14,15 There were no residues in the disallowed
regions of the Ramachandran plot drawn by program PROCHECK.16 Structure figures were generated using PyMOL17 and CCP4MG.18
2626 Recognition of Ubc13 by OspICatalytic site in OspI
We found that the active site of OspI showed
significant conformational changes in the structure of
the complex6,19 (Fig. 3a). In the active-site Cys62 of
wild-type OspI, the S γ position was distantly
positioned compared with that of the cysteine
protease family. However, marked structural
changes were found in the complex in the α2–α3
loop compared with wild-type OspI; Ala62 is shiftedby 2.7 Å, and this acts to extend the α3 helix, which
displaces Cys62 toward the active-site triad.
We next examined whether the conformational
change in the active-site loop can occur in the
uncomplexed OspI C62A mutant. The OspI C62A
mutant protein was crystallized, and its structure was
solved at a resolution of 3.0 Å (Fig. S4). The OspI
C62A crystal structure comprises two molecules in
the asymmetric unit. The overall structures of these
two proteins are similar (r.m.s.d. of 0.3 Å for 192 Cα
2627Recognition of Ubc13 by OspIatoms). We will focus on chain A in the discussion
below. The overall structure of OspI C62A corre-
sponds well with that of the wild type (Fig. S4). TheFig. 2 (legend oactive-site structure of the C62A mutant is similar to
that of the OspI C62A–Ubc13 complex. The side
chain of Ala62 corresponding to Cys62 of OspI isn next page)
2628 Recognition of Ubc13 by OspIturned out toward His145 (Fig. 3a). We previously
reported that the crystal structure of OspI is the
closest to that of AvrPphB, a papain-like cysteine
protease.19 In the superimposed structures, the
catalytic His and main-chain atoms of Cys (Ala for
OspI C62A) and aspartic acids align well in OspI C62A
and AvrPphB (Fig. 3a). At the active site of AvrPphB,
Asn93 functions to form an oxyanion hole. In OspI, a
Gln162 residue is locatedat aposition corresponding to
that of Asn93 in AvrPphB (Fig. 3a). In addition, Gln100
of Ubc13 in the complex protrudes into the active-site
cleft. The distance between Gln100 of Ubc13 and
Ala62 of OspI in the complex suggests that substrate
residue Gln100 can occupy an appropriate position in
wild-type OspI for deamidation (Fig. S5). Recent
studies have identified several bacterial toxins and
type III secreted effectors that act as glutamine
deamidases.20,21 Among these deamidases, Cif family
proteins deamidateGln40 of ubiquitin andNEDD8. The
crystal structures of Cif family proteins complexed with
their substrates have been reported.22,23 Although the
overall structures of OspI and Cifs [Protein Data Bank
(PDB) IDs 4F8C, 4HCN, and 4HCP] and their active
sites are similar (r.m.s.d. range, 4.3–4.4 Å), the
glutamine substrates of Cifs are located about 3.0 Å
closer to the active site than that of OspI (Fig. S6a). The
structures of the interfaces between deamidases and
their substrates have different shape complementarity
and surface charge distribution (Fig. S6b).
The interaction surface on Ubc13
Ubc13 forms a heterodimer with its E2 variant,
Uev1a, and this heterodimer interacts with specific
ubiquitin ligases such as TRAF6 and CHIP (carboxy
terminus of Hsp70-interacting protein). The structures
of Ubc13–Uev1a,11,24 Ubc13–TRAF6,25 and Ubc13–
CHIP26 have been previously determined. The struc-
ture of the Ubc13–Uev1a complex showed that the S2,
S3, and S4 strands and loops S2–S3 and S4–310-1 of
Ubc13 interact with Uev1a. We generated a model of
the Ubc13–Uev1a–OspI complex by superimposing
Ubc13 from the Ubc13–Uev1a and Ubc13–OspI
structures. This model showed that Uev1a is located
at one end of Ubc13, whereas OspI is located at the
other end (Fig. 3b). Previous studies have indicated
that the binding region of TRAF6 and CHIP in Ubc13Fig. 2. Interactions between OspI and Ubc13. (a) Stereo view
(blue) and Ubc13 (orange). Broken lines indicate hydrogen bon
The complementary surface patches (A and B) responsible for
white represent acidic, basic, and neutral, respectively. (c) C
interface. A pull-down assay was performed as described in F
pull-down assay using GST–OspI mutants with wild-type Ub
described in Fig. 1a. GST-bound proteins were pulled down fro
proteins were immunoblotted with anti-S tag and anti-GST anti
GST–OspI and its mutants were expressed in BL21; purified
chromatography, and gel-filtration chromatography; and dialy
GST–OspI or its mutants at 30 °С for 10 min in the reaction buf
DTT). The reaction samples were separated by native PAGEcovers the H1 helix and S3–S4 and 310-1–H2
loops.25,26 TRAF6, CHIP, and OspI recognize Ubc13
through similar interfaces (Fig. 3b and Fig. S7). The
binding of TRAF6 and CHIP to Ubc13 mainly involves
hydrophobic interactions. The interacting surfaces
between OspI and Ubc13 are a hydrophobic surface
and a complementary charged surface. These proteins
have different overall structures but present a very
similar hydrophobic binding surface (Figs. 2b and 3d).
In the crystal structure of Ubc13 complexed with
the deubiquitinating enzyme OTUB1 (OTU-domain-
containing ubiquitin aldehyde-binding protein 1), it
has been recently reported that OTUB1 suppresses
K63-linked polyubiquitination by binding Ubc13.27,28
OTUB1 interacts with Ubc13 through the H1 helix
and S3–S4 and 310-1–H2 loops, which are the same
regions involved in OspI binding (Fig. S7). Further-
more, OTUB1 and Ubc13 interactions are mainly
hydrophobic, as are OpsI–Ubc13 interactions. Al-
though OspI and OTUB1 interact with Ubc13
similarly, OspI inhibits Ubc13 through a different
mechanism. OTUB1 inhibits Ubc13–E3 interaction
by occupying the Ubc13 interface with E3s.27,28
However, the wild-type OspI–Ubc13 complex is not
stable. The deamidation of Gln100 may decrease
the affinity of OspI and TRAF6 for Ubc13.
Next, we compared the structures of free Ubc13
and OspI-bound Ubc13 with the known structures of
three complexes (Ubc13–TRAF6, Ubc13–CHIP, and
Ubc13–OTUB1). The overall structure of Ubc13 is
almost identical among these complexes (r.m.s.d.
range for 146–150 Cα atoms, 1.4–1.7 Å) (Fig. S8).
Their overlapping binding sites in Ubc13 suggest
that a convergence exists in E2 recognition. TRAF6,
CHIP, and OTUB1 interact with not only Ubc13 but
also UbcH5.29–31 However, OspI does not specifi-
cally bind with UbcH5 (Fig. 3c). The complementary
charged interactions between OspI and Ubc13 may
play a key role in specificity determination for Ubc13
(Figs. 2b and 3d and Fig. S9). The Shigella effector
protein IpaH family is a ubiquitin ligase. The IpaH
family was shown to have ubiquitin ligase activity in
the presence of UbcH5 in vitro.32 This substrate
selectivity between these effectors may be an
advantage at different stages of infection.
In summary, we have solved the crystal structures
of the OspI C62A mutant and the OspI C62A–Ubc13of the OspI–Ubc13 interface showing amino acids of OspI
ds. (b) Surface potential representation of OspI and Ubc13.
complex formation are depicted by a circle. Red, blue, and
haracterization of the crucial residues in the OspI–Ubc13
ig. 1a using Ubc13 mutants with GST–OspI C62A (left). A
c13 (right). GST–OspI and its mutants were purified as
m lysates of bacteria expressing Ubc13–S tag. The bound
bodies. (d) Deamidation activities of mutant OspI proteins.
stepwise using affinity chromatography, anion-exchange
zed in reaction buffer. Ubc13 was incubated with purified
fer (20 mM Tris–HCl at pH 7.5, 100 mM NaCl, and 0.1 mM
and stained with Coomassie Brilliant Blue.
Fig. 3. Structural features of the activity of OspI. (a) Stereo view of comparison of the catalytic sites among AvrPphB
(green), OspI WT (purple), OspI C62A (yellow), and Ubc13-bound OspI C62A (cyan). All atoms of His145 and Asp160 were
superimposed on the corresponding residues of the counterpart proteins by LSQKAB in the CCP4 program suite. (b)
Comparison of the Uev1a, TRAF6, CHIP, OTUB1, and OspI binding sites on Ubc13. Ubc13 is shown as a ribbonmodel, and
Uev1a, TRAF6,CHIP, andOTUB1 are shownasCα trace representations and are colored orange (Ubc13), blue (OspI), violet
(Uev1a; PDB code 2C2V), dark green (CHIP; PDB code 2C2V), purple (TRAF6; PDB code 3HCT), gray (OTUB1; PDB code
4DHZ), and light yellow (OTUB1; PDB code 3VON). (c) UbcH5a binding activity ofOspI. A pull-down assaywas performed as
described in Fig. 1a using UbcH5a with GST–OspI C62A. (d) Surface potential representation of the Ubc13 binding site of
TRAF6, CHIP, and OTUB1. The complementary surface patches responsible for complex formation are depicted by a circle.
2629Recognition of Ubc13 by OspI
2630 Recognition of Ubc13 by OspIcomplex. The refined structure in conjunction with
mutational data provided further insight into the
interaction between OspI and Ubc13. Although the
mechanisms through which OspI regulates TRAF6
activity remain unclear, our results have important
consequences for understanding the molecular
basis of the inhibition of TRAF6-dependent inflam-
matory signaling in response to bacterial infection.Accession numbers
Atomic coordinates and structure factors of OspI
C62A and OspI C62A–Ubc13 complex have been
deposited in the Protein Data Bank with accession
numbers 3W30 and 3W31, respectively.
Supplementary data to this article can be found
online at http://dx.doi.org/10.1016/j.jmb.2013.02.037Acknowledgements
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